Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world correlation between sirolimus blood concentration and adverse reactions in transplant patients
ChiCTR2500112928Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in end-stage organ disease, end-stage kidney disease (ESKD) and hepatic disease, sponsored by Shanghai General Hospital. Primary endpoint: Sirolimus blood concentration. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
end-stage organ diseaseend-stage kidney disease (ESKD)hepatic disease
Beyond the preview
Go deeper on ChiCTR2500112928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112928.